MarginsXMarginsX
Home › Markets › Health Care › TIL

Instil Bio Inc. (TIL)

TIL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.75
-5.43% on the day
Market cap
$39.0M
Nano cap
Revenue · 2021
$0
-100.0% on 2020
Net income · 2021
-$156.8M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1789769/000178976922000008/0001789769-22-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.

Profile

FieldValue
TickerTIL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001789769
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNY

Financials · 2021

LineValue
Revenue$0
Net income-$156.8M
Operating income-$155.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$37.6M
Total assets$610.0M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
2.8 months
$5.5M cash at June 30, 2026
Share count, 1 year
+0.5%
2025-08-11 to 2026-08-11 · +4.3% over 3 years
Going-concern doubt
No
10-Q filed August 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"The Company concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$5.5M cash; operating cash flow -$5.9M a quarter.Report 2026-06-30
Shares outstanding6,781,976 (2026-08-11); 6,750,716 a year earlier; 130,079,097 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-08-11
Reverse splits, 3 years1; latest 1-for-20 on 2023-12-08Source 2023-12-08
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2026-04-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.3M-$4.6M$5.5MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$4.2M-$1.3M$5.0MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
Not filed-$8.2M-$7.1M$6.6MNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$13.6M-$10.6M$5.8MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$21.4M-$14.8M$7.7MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$28.2M-$4.2M$15.4MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
Not filed-$11.9M-$10.6M$8.8MNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2024
2024-09-30
Not filed-$23.0M-$20.1M$6.7MNo debt tagsNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-03-31
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 250 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.0%
1 month-1.6%
3 months-16.4%
Year to date-44.7%
1 year-56.3%
From 52-week high-57.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IMAImageneBio Inc.$3.20-7.78%$39.9M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
EXOZeXoZymes Inc.$3.99+4.18%$37.1M
ELUTElutia Inc.$0.8229+0.35%$36.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
INKTMiNK Therapeutics Inc.$9.35+0.11%$48.0M
LONALeonaBio Inc.$3.23-6.92%$30.4M
ELOXEloxx Pharmaceuticals Inc.$12.75-3.04%$51.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier